While HDACi have demonstrated therapeutic utility, many of the first generation compounds are pan-inhibitors.
Features are scored for statistical significance and can be utilized to design improved second generation compounds or more target-focused libraries.
A series of functionalized aryl boronic acids were synthesized and evaluated as potential inhibitors of factor XIa. Crystal structures of the protein inhibitor complexes led to the design and synthesis of second generation compounds showing single digit micromolar inhibition against FXIa and selectivity against thrombin, trypsin, and FXa.
Currently, these inhibitors are pre-clinical compounds; however, there is significant increase in the development of second generation compounds that could be tested in a phase I or II trials.
Many of the first and second generation compounds, like JWH-018 or JWH-007, bare Huffman's initials.
However, MB is the first generation compounds and is not selective for HSP70.
The second generation Spm analogue N -ethyl-N -(cyclopropyl)-methyl-4,8-diazaundecane (CPENSpm) [ 16] has demonstrated lower toxicity and greater therapeutic efficacy than the first generation compounds.
This was achieved by engineering long hydrophobic side chains to the backbone polymer, which maximize hydrophobic interactions with bile acids, adding to the effects of the ionic bonds that bind bile acids in the two first generation compounds.
This change led to a second generation compound with increased potency, a 400-fold enhancement in aqueous solubility at pH 4, and improved dog pharmacokinetics relative to the first generation compound.
The suitable furan diene was obtained by modifying a methacrylate polymer by its reaction with furfural, a first generation compound derived from renewable resources.
PTC124 and NB54 resulted in the similar significant increase in read-through (8.0-fold and 7.9-fold, respectively) followed by a 7.2-fold increase by NB30, the first generation compound (Fig 4B, Table 1).
